Cargando…
Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis
BACKGROUND: Early identification of patients at risk of developing diabetic kidney disease or rapid renal decline is imperative for appropriate patient management, but traditional methods of predicting renal decline are limited. OBJECTIVE: This study evaluated the impact of PromarkerD, a biomarker-b...
Autores principales: | Fusfeld, Lauren, Murphy, Jessica T., Yoon, YooJin, Kam, Li Ying, Peters, Kirsten E., Lin Tan, Pearl, Shanik, Michael, Turchin, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342737/ https://www.ncbi.nlm.nih.gov/pubmed/35913946 http://dx.doi.org/10.1371/journal.pone.0271740 |
Ejemplares similares
-
PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020) -
Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores
por: Peters, Kirsten E., et al.
Publicado: (2023) -
A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease
por: Bringans, Scott, et al.
Publicado: (2020) -
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
por: Bringans, Scott, et al.
Publicado: (2020) -
The Conjoint Course
Publicado: (1907)